Chemed Corp. (CHE) VP Michael D. Witzeman Sells 1,000 Shares
Chemed Corp. (NYSE:CHE) VP Michael D. Witzeman sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the sale, the vice president now directly owns 3,334 shares of the company’s stock, valued at approximately $833,500. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Chemed Corp. (CHE) traded up $1.59 during mid-day trading on Monday, hitting $247.53. The stock had a trading volume of 135,100 shares, compared to its average volume of 94,472. Chemed Corp. has a one year low of $148.84 and a one year high of $248.31. The firm has a market capitalization of $3,952.06, a price-to-earnings ratio of 30.48, a PEG ratio of 5.23 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The company had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. During the same period in the previous year, the company earned $1.73 earnings per share. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. equities analysts expect that Chemed Corp. will post 4.73 EPS for the current fiscal year.
Several equities research analysts recently commented on the company. ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research report on Thursday, November 2nd. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Royal Bank Of Canada upped their price target on Chemed to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday, October 31st. Finally, Oppenheimer upped their price target on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Chemed has a consensus rating of “Hold” and a consensus price target of $236.00.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC acquired a new position in shares of Chemed in the second quarter valued at $120,000. Pacad Investment Ltd. raised its stake in shares of Chemed by 250.0% in the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after purchasing an additional 500 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Chemed by 1,504.5% in the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after purchasing an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Chemed by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after purchasing an additional 83 shares in the last quarter. Finally, MCF Advisors LLC acquired a new position in shares of Chemed in the third quarter valued at $152,000. Institutional investors and hedge funds own 97.75% of the company’s stock.
WARNING: “Chemed Corp. (CHE) VP Michael D. Witzeman Sells 1,000 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/04/chemed-corp-che-vp-michael-d-witzeman-sells-1000-shares.html.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.